Evogene (EVGN) Current Assets (2016 - 2025)
Evogene (EVGN) posted Current Assets of $15.6 million for Q4 2025, down 45.43% sequentially from $28.6 million in Q2 2025, and down 27.6% YoY from $21.6 million in Q4 2024.
Evogene (EVGN) Current Assets (2016 - 2025) Analysis & Trends
Evogene has reported Current Assets for 10 years, with the latest figure at $15.6 million in Q4 2025.
- Quarterly Current Assets fell 27.6% year-over-year to $15.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.6 million (down 27.6% YoY) and the FY2025 annual result came in at $15.6 million, down 27.6% from the prior year.
- Current Assets retreated to $15.6 million in Q4 2025 per EVGN's latest filing, from $28.6 million in the prior quarter.
- Over five years, Current Assets peaked at $67.9 million in Q2 2021 and troughed at $15.6 million in Q4 2025.
- A 5-year average of $36.2 million and a median of $35.1 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2021 and 2022: Current Assets soared 70.33% in 2021, then slumped 44.44% in 2022.
- Over 5 years, Current Assets stood at $56.9 million in 2021, then sank by 33.64% to $37.8 million in 2022, then slipped by 8.69% to $34.5 million in 2023, then tumbled by 37.37% to $21.6 million in 2024, then slipped by 27.6% to $15.6 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $15.6 million, $28.6 million, and $21.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.63 Mn |
| Jun 30, 2025 | 28.65 Mn |
| Dec 31, 2024 | 21.59 Mn |
| Jun 30, 2024 | 25.77 Mn |
| Dec 31, 2023 | 34.47 Mn |
| Jun 30, 2023 | 35.72 Mn |
| Dec 31, 2022 | 37.75 Mn |
| Jun 30, 2022 | 37.71 Mn |
| Dec 31, 2021 | 56.89 Mn |
| Jun 30, 2021 | 67.87 Mn |
| Dec 31, 2020 | 51.82 Mn |
| Jun 30, 2020 | 39.84 Mn |
| Dec 31, 2019 | 49.03 Mn |
| Dec 31, 2018 | 55.49 Mn |
| Dec 31, 2017 | 72.79 Mn |
| Dec 31, 2016 | 89.49 Mn |